DK1719774T3 - Terapeutisk middel mod diabetisk makulaødem - Google Patents

Terapeutisk middel mod diabetisk makulaødem

Info

Publication number
DK1719774T3
DK1719774T3 DK05704239.2T DK05704239T DK1719774T3 DK 1719774 T3 DK1719774 T3 DK 1719774T3 DK 05704239 T DK05704239 T DK 05704239T DK 1719774 T3 DK1719774 T3 DK 1719774T3
Authority
DK
Denmark
Prior art keywords
diabetic
prophylactic
diabetic maculopathy
therapeutic agent
hydrogen atom
Prior art date
Application number
DK05704239.2T
Other languages
English (en)
Inventor
Noriaki Kato
Hiroshi Nagano
Kaori Taniko
Takahito Jomori
Original Assignee
Sanwa Kagaku Kenkyusho Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Co filed Critical Sanwa Kagaku Kenkyusho Co
Application granted granted Critical
Publication of DK1719774T3 publication Critical patent/DK1719774T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/106—Primate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
DK05704239.2T 2004-01-30 2005-01-28 Terapeutisk middel mod diabetisk makulaødem DK1719774T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004022547 2004-01-30
PCT/JP2005/001187 WO2005072066A2 (ja) 2004-01-30 2005-01-28 糖尿病黄斑症の予防又は治療剤

Publications (1)

Publication Number Publication Date
DK1719774T3 true DK1719774T3 (da) 2012-07-16

Family

ID=34823835

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05704239.2T DK1719774T3 (da) 2004-01-30 2005-01-28 Terapeutisk middel mod diabetisk makulaødem

Country Status (12)

Country Link
US (2) US7910615B2 (da)
EP (1) EP1719774B1 (da)
JP (2) JP4014053B2 (da)
KR (1) KR101111411B1 (da)
CN (1) CN100537574C (da)
AT (1) ATE555117T1 (da)
AU (1) AU2005207906B2 (da)
CA (1) CA2554679C (da)
DK (1) DK1719774T3 (da)
ES (1) ES2386094T3 (da)
PL (1) PL1719774T3 (da)
WO (1) WO2005072066A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101325952B (zh) * 2005-12-16 2012-02-08 株式会社三和化学研究所 用于急性肾衰竭的预防和治疗剂
EP1987829A4 (en) * 2006-02-20 2009-07-29 Sanwa Kagaku Kenkyusho Co PROPHYLACTIC OR THERAPEUTIC AGENT FOR LESIONS DUE TO BRAIN ISCHEMIA OR LESIONS DUE TO BRAIN ISCHEMIA WITH REPERFUSION IN BRAIN VASCULAR ACCIDENTS
JP5363123B2 (ja) * 2007-01-31 2013-12-11 株式会社三和化学研究所 網膜神経又は視神経の保護剤
KR20090121376A (ko) * 2007-03-07 2009-11-25 교린 세이야꾸 가부시키 가이샤 글루코키나아제 활성화 물질
CN102711756A (zh) * 2010-01-14 2012-10-03 株式会社三和化学研究所 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物
AU2011246232A1 (en) 2010-04-28 2012-11-01 Sanwa Kagaku Kenkyusho Co., Ltd. Prophylactic or therapeutic medication for inner ear disorders
US20140302009A1 (en) * 2011-02-02 2014-10-09 Sanwa Kagaku Kenkyusho Co., Ltd. Medicinal Agent for Prevention or Treatment of Diseases Associated with Intraocular Neovascularization and/or Intraocular Vascular Hyperpermeability
JP2015110525A (ja) * 2012-04-02 2015-06-18 株式会社三和化学研究所 歯肉炎の予防又は治療のための医薬
JP6187985B2 (ja) * 2015-07-14 2017-08-30 国立大学法人佐賀大学 ノックアウト非ヒト動物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61200991A (ja) * 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
JP2672949B2 (ja) 1987-10-20 1997-11-05 株式会社芝浦製作所 エミッションコントロール装置
JP2976230B2 (ja) * 1989-12-20 1999-11-10 大塚製薬株式会社 糖尿病ラット
JP3025917B2 (ja) * 1990-12-19 2000-03-27 大塚製薬株式会社 インシュリン非依存性糖尿病ラット
US5639482A (en) * 1993-11-10 1997-06-17 Crary; Ely J. Composition for control and prevention of diabetic retinopathy
JPH07242547A (ja) * 1994-03-02 1995-09-19 Sanwa Kagaku Kenkyusho Co Ltd 糖尿病性単純網膜症の進行阻止剤乃至治療剤
JP3072226B2 (ja) * 1994-06-20 2000-07-31 日本原子力研究所 デカボランガス供給システムにおけるデカボラン供給方法
EP0719556B1 (en) 1994-12-28 2000-10-25 Sanwa Kagaku Kenkyusho Co., Ltd. Use of (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamide for treating diabetic keratopathy
JP3603129B2 (ja) * 1994-12-28 2004-12-22 株式会社三和化学研究所 糖尿病性角膜症の治療剤
JPH09301861A (ja) * 1996-05-13 1997-11-25 Showa Denko Kk ラジカル疾患用注射・点滴薬剤
WO1998019523A1 (fr) * 1996-11-01 1998-05-14 Shionogi & Co., Ltd. Souris modele pour maladies affectant l'homme
KR100560002B1 (ko) * 1998-02-06 2006-03-13 씨씨아이 가부시키가이샤 허혈 재관류 장해 예방 및 치료제
US6479729B1 (en) * 1998-02-06 2002-11-12 The Johns Hopkins University Mouse model for ocular neovascularization
JP2000270713A (ja) * 1999-03-23 2000-10-03 Kennetto:Kk 糖尿病態モデル動物及びその製造方法並びに糖尿病態モデル動物の選定方法
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
US20020068740A1 (en) 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications

Also Published As

Publication number Publication date
ATE555117T1 (de) 2012-05-15
PL1719774T3 (pl) 2012-09-28
CA2554679C (en) 2012-09-25
JP4014053B2 (ja) 2007-11-28
US7910615B2 (en) 2011-03-22
KR20060126547A (ko) 2006-12-07
AU2005207906A1 (en) 2005-08-11
KR101111411B1 (ko) 2012-03-13
EP1719774A4 (en) 2009-05-06
US8097640B2 (en) 2012-01-17
WO2005072066A3 (ja) 2005-10-06
AU2005207906B2 (en) 2009-10-22
EP1719774A2 (en) 2006-11-08
CN1914211A (zh) 2007-02-14
CA2554679A1 (en) 2005-08-11
EP1719774B1 (en) 2012-04-25
JP2008029346A (ja) 2008-02-14
JPWO2005072066A1 (ja) 2007-09-06
US20070293556A1 (en) 2007-12-20
CN100537574C (zh) 2009-09-09
US20100305177A1 (en) 2010-12-02
WO2005072066A2 (ja) 2005-08-11
ES2386094T3 (es) 2012-08-08

Similar Documents

Publication Publication Date Title
DK1719774T3 (da) Terapeutisk middel mod diabetisk makulaødem
WO2005072066A1 (ja) 糖尿病黄斑症の予防又は治療剤
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
EP1614676A4 (en) PHOSPHORUS TRANSPORT IN VIVO INHIBITOR COMPOUND AND MEDICAMENT CONTAINING THE SAME
BR0314761A (pt) Composto de adenina e seu uso
EP1803721A4 (en) INNOVATIVE GLUCITOL DERIVATIVE, PRECURSOR OF THE MEDICINAL PRODUCT AND SALT THEREOF, AND A THERAPEUTIC AGENT FOR DIABETES CONTAINING THE SAME
TWI350170B (en) Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
BRPI0507984A (pt) composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
NZ530782A (en) Aminoisoxazole derivatives active as kinase inhibitors
EP1792927A4 (en) NEW BLOCK COPOLYMER, MICELLA PREPARATION AND ANTICROPHIDE CONTAINING THIS AS ACTIVE INGREDIENTS
NO20065904L (no) Terapeutiske forbindelser
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
DK1778680T3 (da) Spirocykliske cyclohexaderivater
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
AR054272A1 (es) Derivados de 3- aminopirrilidinas tri, tetra - sustituidos
RU2012134639A (ru) Фармацевтический препарат для предупреждения и лечения нарушений, сопровождающихся глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза
WO2008008701A3 (en) Substituted cyclopentane derivatives as therapeutic agents
US6436944B1 (en) Combination effective for the treatment of impotence
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
WO2008093691A1 (ja) 網膜神経又は視神経の保護剤
JP2007527903A5 (da)